WILLIAM THOMAS SHERMAN
Pharmacy in Hendersonville, NC
License number
Pennsylvania RP025460L
Category
Pharmacy
Type
Pharmacist
Address
Address
2
Hendersonville, NC 28739
Pennsylvania
Pennsylvania
Personal information
See more information about WILLIAM THOMAS SHERMAN at radaris.comName
Address
Phone
505 E Fairfield Ave, New Castle, PA 16105
520 Franklin Church Rd, Dillsburg, PA 17019
537 E Maine Ave, Southern Pines, NC 28387
540 Sarah St, Stroudsburg, PA 18360
476 Allentown Rd, Souderton, PA 18964
Professional information
(-)-Pseudoephedrine As A Sympathomimetic Drug
US Patent:
6495529, Dec 17, 2002
Filed:
Apr 16, 2001
Appl. No.:
09/743052
Inventors:
Anthony Booth - Chester NJ
William T. Sherman - Hendersonville NC
Peter Raven - Forth Worth TX
James L. Caffrey - Burelson TX
Thomas Yorio - Burelson TX
Michael Forster - Fort Worth TX
Patricia Gwirtz - Forth Worth TX
William T. Sherman - Hendersonville NC
Peter Raven - Forth Worth TX
James L. Caffrey - Burelson TX
Thomas Yorio - Burelson TX
Michael Forster - Fort Worth TX
Patricia Gwirtz - Forth Worth TX
Assignee:
Warner-Lambert Company - Morris Plains NJ
International Classification:
A61K 31135
US Classification:
514 55, 514648, 514649, 514912
Abstract:
The present invention provides pharmaceutical compositions which include (-)-pseudoephedrine and a pharmaceutically acceptable carrier, wherein the (-)-pseudoephedrine is substantially-free of (+)-pseudoephedrine. In another embodiment, the present invention provides methods of relieving nasal and bronchial congestion and of inducing pupil dilation which include administering a pharmaceutically effective amount of (-)-pseudoephedrine to a mammal. The (-)-pseudoephedrine used in the present methods is substantially free of (+)-pseudoephedrine and also substantially free of side effects caused by administration of (+)-pseudoephedrine.
Treatment Of Osteoarthritis By Administering Poly-N-Acetyl-D-Glucosamine
US Patent:
6117851, Sep 12, 2000
Filed:
Dec 12, 1997
Appl. No.:
8/990161
Inventors:
William T. Sherman - Hendersonville NC
Robert W. Gracy - Fort Worth TX
Robert W. Gracy - Fort Worth TX
Assignee:
Lescarden Inc. - New York NY
International Classification:
A61K 3170
US Classification:
514 62
Abstract:
The methods of the present invention relate to administering to a mammal afflicted with osteoarthritis an effective amount of poly-N-acetyl-D-glucosamine (poly-NAG), partially depolimerized poly-NAG, pharmaceutically acceptable salts of poly-NAG, or mixtures thereof, to treat osteoarthritis and/or alleviate the symptoms of osteoarthritis such as pain, joint tenderness and swelling and impaired joint mobility. The present invention also comprises solid and liquid pharmaceutical dosage forms comprising poly-NAG, its pharmaceutically acceptable salts and mixtures thereof. These dosage forms may be administered orally and by-injection to treat osteoarthritis and/or alleviate the symptoms thereof.
(-)-Pseudoephedrine As A Sympathomimetic Drug
US Patent:
2003011, Jun 26, 2003
Filed:
Oct 16, 2002
Appl. No.:
10/272745
Inventors:
Anthony Booth - Chester NJ, US
William Sherman - Hendersonville NC, US
Peter Raven - Fort Worth TX, US
James Caffrey - Burelson TX, US
Thomas Yorio - Burelson TX, US
Michael Forester - Fort Worth TX, US
Paticia Gwirtz - Fort Worth TX, US
William Sherman - Hendersonville NC, US
Peter Raven - Fort Worth TX, US
James Caffrey - Burelson TX, US
Thomas Yorio - Burelson TX, US
Michael Forester - Fort Worth TX, US
Paticia Gwirtz - Fort Worth TX, US
International Classification:
A61K031/137
US Classification:
514/649000
Abstract:
The present invention provides pharmaceutical compositions which include (-)-pseudoephedrine and a pharmaceutically acceptable carrier, wherein the (-)-pseudoephedrine is substantially-free of (+)-pseudoephedrine. In another embodiment, the present invention provides methods of relieving nasal and bronchial congestion and of inducing pupil dilation which include administering a pharmaceutically effective amount of (-)-pseudoephedrine to a mammal. The (-)-pseudoephedrine used in the present methods is substantially free of (+)-pseudoephedrine and also substantially free of side effects caused by administration of (+)-pseudoephedrine.
(-)-Pseudoephedrine As A Sympathomimetic Drug
US Patent:
2008024, Oct 2, 2008
Filed:
Jul 13, 2006
Appl. No.:
11/485928
Inventors:
Anthony Booth - Chester NJ, US
William T. Sherman - Hendersonville NC, US
Peter Raven - Fort Worth TX, US
James L. Caffrey - Burelson TX, US
Thomas Yorio - Burelson TX, US
Michael Forster - Fort Worth TX, US
Patricia Gwirtz - Fort Worth TX, US
William T. Sherman - Hendersonville NC, US
Peter Raven - Fort Worth TX, US
James L. Caffrey - Burelson TX, US
Thomas Yorio - Burelson TX, US
Michael Forster - Fort Worth TX, US
Patricia Gwirtz - Fort Worth TX, US
International Classification:
A61K 31/137, A61P 11/00
US Classification:
514653
Abstract:
The present invention provides pharmaceutical compositions which include (−)-pseudoephedrine and a pharmaceutically acceptable carrier, wherein the (−)-pseudoephedrine is substantially-free of (+)-pseudoephedrine. In another embodiment, the present invention provides methods of relieving nasal and bronchial congestion and of inducing pupil dilation which include administering a pharmaceutically effective amount of (−)-pseudoephedrine to a mammal. The (−)-pseudoephedrine used in the present methods is substantially free of (+)-pseudoephedrine and also substantially free of side effects caused by administration of (+)-pseudoephedrine.
Treatment Of Osteoarthritis By Administering Poly-N-Acetyl-D-Glucosamine
US Patent:
2001001, Aug 16, 2001
Filed:
Feb 9, 2001
Appl. No.:
09/780237
Inventors:
William Sherman - Hendersonville NC, US
Robert Gracy - Fort Worth TX, US
Robert Gracy - Fort Worth TX, US
Assignee:
Lescarden, Inc.
International Classification:
A61K031/715
US Classification:
514/062000, 514/054000
Abstract:
The methods of the present invention relate to administering to a mammal afflicted with osteoarthritis an effective amount of poly-N-acetyl-D-glucosamine (poly-NAG), partially depolimerized poly-NAG, pharmaceutically acceptable salts of poly-NAG, or mixtures thereof, to treat osteoarthritis and/or alleviate the symptoms of osteoarthritis such as pain, joint tenderness and swelling and impaired joint mobility. The present invention also comprises solid and liquid pharmaceutical dosage forms comprising poly-NAG, its pharmaceutically acceptable salts and mixtures thereof. These dosage forms may be administered orally and by-injection to treat osteoarthritis and/or alleviate the symptoms thereof.